PMC8419523_01
The patient is initially hypertensive and tachycardic. At hour 4, dexmedetomidine was introduced and the patient's vital signs began to improve.
CRICC2021-7590960.001.jpg
PMC8419523_01_CRICC2021-7590960.001.jpg
fig1
The patient's heart rate and blood pressure appropriately decreased (Figure 1).
PMC8419523_02
The patient had persistent tachycardia and hypertension despite multiple doses of lorazepam noted at hours 3-5. Dexmedetomidine was initiated at hour 12, and the patient had a significant improvement in vitals by hour 14 with mild increase in dose.
CRICC2021-7590960.002.jpg
PMC8419523_02_CRICC2021-7590960.002.jpg
fig2
She was started on dexmedetomidine at a dose of 0.3 mcg/kg/hr and slowly titrated to 0.7 mcg/kg/hr, which steadily improved her agitation and brought an appropriate resolution of her tachycardia and hypertension (Figure 2).